Equities

Neogen Corp

Neogen Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)15.34
  • Today's Change-1.06 / -6.46%
  • Shares traded2.74m
  • 1 Year change+1.59%
  • Beta1.2481
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy1
Outperform1
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 2 analysts offering 12 month price targets for Neogen Corp have a median target of 18.75, with a high estimate of 21.00 and a low estimate of 16.50. The median estimate represents a 22.23% increase from the last price of 15.34.
High36.9%21.00
Med22.2%18.75
Low7.6%16.50

Earnings history & estimates in USD

On Oct 10, 2024, Neogen Corp reported 1st quarter 2025 earnings of 0.07 per share.
The next earnings announcement is expected on Jan 07, 2025.
Average growth rate-9.39%
Neogen Corp reported annual 2024 earnings of 0.45 per share on Jul 30, 2024.
Average growth rate-3.84%
More ▼

Revenue history & estimates in USD

Neogen Corporation had 1st quarter 2025 revenues of 216.96m. This bettered the 215.06m consensus of the 3 analysts covering the company. This was 5.25% below the prior year's 1st quarter results.
Average growth rate-1.24%
Neogen Corporation had revenues for the full year 2024 of 924.22m. This was 12.37% above the prior year's results.
Average growth rate+23.24%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.